- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01510613
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
March 8, 2018 updated by: Giampaolo Merlini, IRCCS Policlinico S. Matteo
An Open-label, Phase II Study of Pomalidomide and Dexamethasone (PDex) for Previously Treated Patients With AL Amyloidosis.
The aim of the study is to evaluate the safety and efficacy of Pomalidomide and Dexamethasone in patients who did not achieve a complete response after initial treatment with both an alkylating agent (Melphalan or Cyclophosphamide) and Bortezomib.
Patients who received 1 previous treatment without achieving a complete response (CR), but who could not be treated with alkylators and/or Bortezomib due to contraindications, will be included.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This will be a phase II open-label single-arm dose-escalation study.
Patients with systemic AL amyloidosis who did not achieve a complete response after initial treatment with both an alkylating agent (Melphalan or Cyclophosphamide) and Bortezomib will be enrolled.
Patients who received 1 previous treatment, but who could not be treated with alkylators and/or Bortezomib due to contraindications, will be eligible.
Twenty-eight patients will be enrolled in the study.
The patients will be treated with the combination of Pomalidomide and Dexamethasone given orally in 28 day cycles continuously, i.e. until hematologic or organ progression or unacceptable toxicity.
There will be 2 dose levels of Pomalidomide (2 and 4 mg/day).
A standard 3+3 dose escalation design will be used.
If less than 2 of 6 patient experience dose limiting toxicity at dose level 1, then all other patients will be treated at dose level 2. There will be 2 dose levels also for Dexamethasone (20 and 40 mg/week).
The dose of dexamethasone will be adjusted on an individual basis, considering fluid retention and repetitive ventricular arrhythmias at baseline, as well as Dexamethasone-related adverse events.
The study comprises 3 periods: screening, treatment (with evaluations of response at the end of every single cycle) followed by the end-of-treatment evaluation and follow-up.
After giving written informed consent, subjects will be evaluated for eligibility for enrollment in the study and baseline evaluations will be performed.
Treatment will be continued until progression or unacceptable toxicity is observed.
After treatment discontinuation, patients will be followed for survival and any possible Second Primary Malignancies signals for 2 years.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Pavia, Italy, 27100
- Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- At least 18 years.
- Diagnosis of systemic AL amyloidosis.
- Symptomatic organ (heart, kidney, liver, peripheral nervous system, or soft tissue) involvement.
- Patients achieving less than complete response after initial treatment with an alkylating agent (melphalan or cyclophosphamide) and bortezomib. Patients with AL amyloidosis who received 1 previous treatment, but who could not be treated with alkylators and/or bortezomib due to contraindications, will be eligible.
- Measurable disease: difference between amyloidogenic (involved) and uninvolved free light chains (dFLC) > 50 mg/L.
- Hb ≥ 10 g/dL
- ANC ≥ 1500/uL.
- Platelet count ≥ 100000/uL.
- eGFR ≥ 30 mL/min per 1.73 m2.
- Performance status (ECOG) < 3.
- Total bilirubin < 2.5 mg/dL.
- Alkaline phosphatase < 5 × url.
- ALT < 3 × url.
- Female: FCBP must have two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug. The first pregnancy test must be performed within 10-14 days prior to the start of study drug and the second pregnancy test must be performed within 24 hours prior to the start of study drug. The subject may not receive study drug until the Investigator has verified that the results of these pregnancy tests are negative. Will be warned that sharing study drug is prohibited and will be counseled about pregnancy precautions and potential risks of fetal exposure. Must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from the study.
- Male: Must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy. Will be warned that sharing study drug is prohibited and will be counseled about pregnancy precautions and potential risks of fetal exposure. Must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from the study.
During study participation and for 28 days following discontinuation from the study:
- All subjects: No more than a 28-day supply of study drug will be dispensed at a time.
- Female: FCBP with regular cycles must agree to have pregnancy tests weekly for the first 28 days of study participation and then every 28 days while on study, at study discontinuation, and at day 28 following discontinuation from the study. If menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 days and then every 14 days while on study, at study discontinuation, and at days 14 and 28 following discontinuation from the study. In addition to the required pregnancy testing, the Investigator must confirm with FCBP that she is continuing to use two reliable methods of birth control at each visit. Counseling about pregnancy precautions and the potential risks of fetal exposure must be conducted at a minimum of every 28 days. During counseling, subjects must be reminded to not share study drug and to not donate blood. Pregnancy testing and counseling must be performed if a subject misses her period or if her pregnancy test or her menstrual bleeding is abnormal. Study drug treatment must be discontinued during this evaluation. Females must agree to abstain from breastfeeding during study participation and for at least 28 days after discontinuation from the study.
- Male: Counseling about the requirement for latex condom use during sexual contact with females of childbearing potential and the potential risks of fetal exposure must be conducted at a minimum of every 28 days. During counseling, subjects must be reminded to not share study drug and to not donate blood, sperm, or semen.
Exclusion Criteria:
- Amyloid-specific syndrome, such as carpal tunnel syndrome or skin purpura as the only evidence of disease.
- New York Heart association (NYHA) class IV.
- Known positivity for HIV or active hepatitis infection.
- Pregnant or nursing women (men must agree to use an acceptable method for contraception for the duration of the study).
- Uncontrolled infections.
- Other active malignancies.
- Patient has a prior history of thrombosis or venous thromboembolism or pulmonary embolism.
- Known hypersensitivity to thalidomide or lenalidomide including development of erythema.
- Previous or ongoing psychiatric illness (with the exclusion of reactive depression).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pomalidomide and Dexamethasone
|
Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of PDex
Time Frame: evaluation made at the end of each 28 days cycle
|
To evaluate the efficacy of PDex in patients who did not achieve a complete response after initial treatment with both an alkylating agent (Melphalan or Cyclophosphamide) and Bortezomib.
|
evaluation made at the end of each 28 days cycle
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of PDex
Time Frame: evaluation made at the end of each 28 days cycle
|
to assess the safety of PDex combination and to assess the survival of AL Amyloidosis patients treated with PDex.
|
evaluation made at the end of each 28 days cycle
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Giampaolo Merlini, Prof., Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011 May 10;29(14):1924-33. doi: 10.1200/JCO.2010.32.2271. Epub 2011 Apr 11.
- Palladini G, Russo P, Lavatelli F, Nuvolone M, Albertini R, Bosoni T, Perfetti V, Obici L, Perlini S, Moratti R, Merlini G. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009 Apr;88(4):347-50. doi: 10.1007/s00277-008-0600-y. Epub 2008 Sep 9.
- Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, Stewart AK, Laumann K, Allred JB, Mandrekar SJ, Rajkumar SV. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009 Oct 20;27(30):5008-14. doi: 10.1200/JCO.2009.23.6802. Epub 2009 Aug 31.
- Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, Garderet L, Belhadj K, Dorvaux V, Minvielle S, Moreau P; IFM and MAG groups. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia. 2010 Mar;24(3):623-8. doi: 10.1038/leu.2009.273. Epub 2010 Jan 14.
- Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood. 2017 Apr 13;129(15):2120-2123. doi: 10.1182/blood-2016-12-756528. Epub 2017 Jan 27.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
January 11, 2012
First Submitted That Met QC Criteria
January 13, 2012
First Posted (Estimate)
January 16, 2012
Study Record Updates
Last Update Posted (Actual)
March 12, 2018
Last Update Submitted That Met QC Criteria
March 8, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Paraproteinemias
- Proteostasis Deficiencies
- Neoplasms, Plasma Cell
- Immunoglobulin Light-chain Amyloidosis
- Amyloidosis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Pomalidomide
Other Study ID Numbers
- AC-007-IT
- 2011-001787-22 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Amyloidosis of Light Chain Type
-
IRCCS Policlinico S. MatteoTerminatedPrimary Amyloidosis of Light Chain TypeItaly
-
National Cancer Institute (NCI)CompletedPrimary Systemic Amyloidosis | Light Chain Deposition DiseaseUnited States
-
Millennium Pharmaceuticals, Inc.CompletedLight-Chain AmyloidosisUnited States, Canada, France, Germany, Italy
-
Criterium, Inc.AmgenCompletedAmyloidosis | Systemic Light Chain AmyloidosisUnited States
-
Peking Union Medical College HospitalRecruitingLight Chain (AL) Amyloidosis | Venetoclax | CCND1 TranslocationChina
-
Alfred Chung, MDAbbVie; Janssen PharmaceuticalsRecruitingAL Amyloidosis | Light Chain (AL) Amyloidosis | Systemic Light Chain DiseaseUnited States
-
The Cleveland ClinicCompletedAmyloidosis | Spinal Stenosis | Amyloid | Transthyretin Amyloidosis | Primary Amyloidosis of Light Chain TypeUnited States
-
Tufts Medical CenterSanofiWithdrawnAmyloidosis | Light Chain (AL) Amyloidosis
-
TakedaTerminatedRelapsed or Refractory Systemic Light Chain AmyloidosisUnited States, Canada, Spain, Israel, France, Australia, Denmark, Germany, Korea, Republic of, Greece, Netherlands, Brazil, Czechia, Italy, United Kingdom
-
Guangdong Provincial People's HospitalRecruitingImmunoglobulin Light-Chain AmyloidosisChina
Clinical Trials on Pomalidomide and Dexamethasone
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
National University Hospital, SingaporeCelgeneUnknownMultiple Myeloma | Relapse After Use of Lenalidomide and BortezomibSingapore
-
Peking University People's HospitalQingdao Municipal HospitalRecruiting
-
Seagen Inc.Terminated
-
CelgeneCompletedMultiple MyelomaAustria, Italy, France, Spain, Netherlands, Germany, Greece, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Multiple Myeloma Research ConsortiumBristol-Myers Squibb; Memorial Sloan Kettering Cancer Center; Washington University... and other collaboratorsActive, not recruitingMultiple Myeloma | Relapsed Refractory Multiple MyelomaUnited States
-
Canadian Myeloma Research GroupGlaxoSmithKlineRecruitingRelapsed and/or Refractory Multiple MyelomaCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
CelgeneCelgene CorporationCompletedMultiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in RelapseUnited States, Australia